INIS
patients
100%
cancer
99%
lung cells
70%
lungs
61%
mutants
53%
mutations
31%
adenocarcinomas
30%
tumors
28%
populations
23%
hiv
23%
growth factors
23%
correlations
23%
immunotherapy
23%
diseases
23%
esophagus
23%
genetics
23%
lymphomas
23%
receptors
23%
breasts
23%
metastases
23%
gene amplification
23%
membranes
18%
carcinomas
18%
tyrosine
11%
kinases
11%
amplification
11%
oncogenes
6%
control
5%
data
5%
Medicine and Dentistry
Non Small Cell Lung Cancer
70%
Epidermal Growth Factor Receptor
65%
Lung Cancer
57%
Programmed Death-Ligand 1
46%
Primary Tumor
40%
Lung Adenocarcinoma
38%
Neoplasm
36%
Retrospective Study
31%
Diagnosis
23%
Non-Hodgkin Lymphoma
23%
Human Immunodeficiency Virus
23%
B Cell
23%
Breast Cancer
23%
Gene Amplification
23%
Diseases
23%
Fine-Needle Aspiration
23%
Immunotherapy
23%
Epidermal Growth Factor Receptor Kinase Inhibitor
23%
Diffuse Large B-Cell Lymphoma
14%
Overall Survival
13%
Burkitt's Lymphoma
11%
Endobronchial Ultrasonography
9%
B-Cell Lymphoma
8%
Tumor Immune Microenvironment
7%
Oncogene
7%
Progression Free Survival
7%
Cancer Surgery
5%
Targeted Therapy
5%
Osimertinib
5%
Surgery
5%
Local Therapy
5%
Pharmacology, Toxicology and Pharmaceutical Science
Lung Cancer
52%
Epidermal Growth Factor Receptor
46%
Primary Tumor
40%
Neoplasm
36%
Lung Adenocarcinoma
35%
Retrospective Study
29%
Immunotherapy
23%
Disease
23%
Epidermal Growth Factor Receptor Kinase Inhibitor
23%
Breast Cancer
23%
Non Small Cell Lung Cancer
23%
Overall Survival
11%
Osimertinib
5%
Progression Free Survival
5%
